KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075
Debt
Debt-to-Equity RatioN/A
Current Ratio2.41
Quick Ratio2.41
Price-To-Earnings
Trailing P/E Ratio-12.69
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.39 million
Price / Sales39.77
Cash FlowN/A
Price / CashN/A
Book Value$2.52 per share
Price / Book7.71
Profitability
EPS (Most Recent Fiscal Year)($1.53)
Net Income$-15,800,000.00
Net Margins-132.38%
Return on Equity-56.24%
Return on Assets-28.87%
Miscellaneous
Employees33
Outstanding Shares17,180,000
Market Cap$379.83 million
Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions
What is Kalvista Pharmaceuticals' stock symbol?
Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."
How were Kalvista Pharmaceuticals' earnings last quarter?
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) issued its quarterly earnings data on Friday, September, 14th. The specialty pharmaceutical company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.14. The specialty pharmaceutical company had revenue of $3.72 million for the quarter, compared to the consensus estimate of $4.11 million. Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. View Kalvista Pharmaceuticals' Earnings History.
When is Kalvista Pharmaceuticals' next earnings date?
What price target have analysts set for KALV?
4 equities research analysts have issued 12 month target prices for Kalvista Pharmaceuticals' shares. Their predictions range from $20.00 to $32.00. On average, they expect Kalvista Pharmaceuticals' share price to reach $26.3333 in the next year. This suggests a possible upside of 35.6% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.
What is the consensus analysts' recommendation for Kalvista Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.
What are Wall Street analysts saying about Kalvista Pharmaceuticals stock?
Here are some recent quotes from research analysts about Kalvista Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. " (9/20/2018)
- 2. BTIG Research analysts commented, "Another Beat-and-Raise; Reiterate Buy and $260 PT TMO kicked off 2018 on a strong note, with 7% organic revenue growth (against 4% growth in 1Q17) and 20% EPS growth (upside from guidance largely driven by higher organic growth, and less so from more favorable FX), handily beating consensus expectations. Full year guidance was raised: 1) on the top, to reflect (roughly in equal parts of) better organic revenue growth (5% from 4-5% prior), greater Patheon acquisition contribution, and more favorable FX; and 2) on the bottom, stronger 1Q operational performance and more favorable FX, partially offset by small dilution from a recent bolt-on. Strong performance was broad-based, although standouts in the quarter include the biopharma customer segment (+10% y/y), China (high-teens growth), and Analytical Instruments (+13% organic growth; strength across FEI, chromatography / MS, chemical analysis). While TMO has a strong financial performance track record, we think the company is currently better positioned than ever to capitalize on a relatively strong end market environment (e.g., biopharma, industrial) and take market share to drive top line growth, continue to execute on operational efficiency (e.g., Patheon acquisition synergy targets tracking ahead of expectations), and maximize capital deployment opportunities (3.8x leverage ratio at quarter-end vs. 3.75x estimated year-end average; ~$500mm share buyback targeted for 2H; active M&A pipeline; rising interest rates already factored into longer-term forecasts and strategic planning). Our PT gets valuation closer to the peer average on a forward P/E basis." (4/29/2018)
Who are some of Kalvista Pharmaceuticals' key competitors?
Some companies that are related to Kalvista Pharmaceuticals include TherapeuticsMD (TXMD), Biohaven Pharmaceutical (BHVN), Wave Life Sciences (WVE), Deciphera Pharmaceuticals (DCPH), ImmunoGen (IMGN), IMMURON Ltd/S (IMRN), Uniqure (QURE), Impax Laboratories (IPXL), Tricida (TCDA), Kiniksa Pharmaceuticals (KNSA), Endocyte (ECYT), Vanda Pharmaceuticals (VNDA), Esperion Therapeutics (ESPR), Intra-Cellular Therapies (ITCI) and Omeros (OMER).
Who are Kalvista Pharmaceuticals' key executives?
Kalvista Pharmaceuticals' management team includes the folowing people:
- Mr. Thomas Andrew Crockett M.B.A., CEO & Director (Age 43)
- Mr. Benjamin L. Palleiko, Chief Financial Officer (Age 52)
- Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 55)
- Mr. John B. McKune, VP of Fin. (Age 42)
- Dr. Edward P. Feener Ph.D., Chief Scientific Officer (Age 58)
Who are Kalvista Pharmaceuticals' major shareholders?
Kalvista Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Interwest Venture Management Co. (2.26%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Holdings A/S Novo and Rajeev M Shah. View Institutional Ownership Trends for Kalvista Pharmaceuticals.
Which major investors are buying Kalvista Pharmaceuticals stock?
KALV stock was purchased by a variety of institutional investors in the last quarter, including Interwest Venture Management Co.. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha and Rajeev M Shah. View Insider Buying and Selling for Kalvista Pharmaceuticals.
How do I buy shares of Kalvista Pharmaceuticals?
Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kalvista Pharmaceuticals' stock price today?
One share of KALV stock can currently be purchased for approximately $19.42.
How big of a company is Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals has a market capitalization of $379.83 million and generates $8.39 million in revenue each year. The specialty pharmaceutical company earns $-15,800,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.
What is Kalvista Pharmaceuticals' official website?
How can I contact Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]
MarketBeat Community Rating for Kalvista Pharmaceuticals (NASDAQ KALV)
MarketBeat's community ratings are surveys of what our community members think about Kalvista Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.
